Guggenheim Capital LLC Acquires New Position in Sanofi (NASDAQ:SNY)

Guggenheim Capital LLC purchased a new position in Sanofi (NASDAQ:SNY - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 6,118 shares of the company's stock, valued at approximately $295,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. State Street Corp increased its stake in Sanofi by 0.5% during the 3rd quarter. State Street Corp now owns 56,734 shares of the company's stock valued at $3,270,000 after buying an additional 264 shares during the period. Barclays PLC raised its position in Sanofi by 107.5% during the third quarter. Barclays PLC now owns 639,772 shares of the company's stock valued at $36,869,000 after buying an additional 331,445 shares during the period. Geode Capital Management LLC lifted its position in shares of Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock worth $14,681,000 after purchasing an additional 16,780 shares in the last quarter. World Investment Advisors LLC raised its holdings in shares of Sanofi by 1,020.5% during the third quarter. World Investment Advisors LLC now owns 48,430 shares of the company's stock worth $2,791,000 after acquiring an additional 44,108 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Sanofi during the 3rd quarter valued at about $219,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Price Performance

Sanofi stock traded up $1.24 on Friday, reaching $55.34. The company's stock had a trading volume of 824,740 shares, compared to its average volume of 2,348,745. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a market cap of $139.80 billion, a price-to-earnings ratio of 22.23, a PEG ratio of 1.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The business's fifty day moving average price is $54.52 and its 200 day moving average price is $52.06.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. The company's revenue was down 11.0% on a year-over-year basis. Equities analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be paid a $2.0369 dividend. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date is Friday, May 9th. Sanofi's dividend payout ratio (DPR) is 57.14%.

Wall Street Analyst Weigh In

Several equities analysts have commented on SNY shares. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. BNP Paribas began coverage on Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. The Goldman Sachs Group initiated coverage on Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi currently has an average rating of "Buy" and a consensus target price of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.